


# Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

1. (currently amended) A compound of formula (I):



wherein

W is -COOH, or -(CO)NH<sub>2</sub>, or -(SO<sub>2</sub>)NH<sub>2</sub>;

Q is N or CH;

R<sub>a</sub> and R<sub>b</sub> are independently selected from -H and halogen;


R<sub>c</sub> is absent or is independently selected from the group consisting of -OH, -CF<sub>3</sub>, -C<sub>1-4</sub>alkyl, -OC<sub>1-4</sub>alkyl, -NO<sub>2</sub> and halo;

Z is selected from the group consisting of


a) >C=O, >C=CHR<sub>f</sub>, >CR<sub>d</sub>R<sub>g</sub>, >CF<sub>2</sub>, >CR<sub>d</sub>OR<sub>e</sub>, >C(OR<sub>d</sub>)OR<sub>e</sub>;

b) >C(R<sub>d</sub>)NR<sub>d</sub>R<sub>g</sub>;

c) -SO<sub>2</sub>NR<sub>d</sub>C(R<sub>h</sub>)<sub>2</sub>;



where A is fused at the b or c faces, at a face of A which contains two carbon atoms, which is saturated or unsaturated;



where A is fused at the b or c faces, at a face of A which contains two carbon atoms, which is saturated or unsaturated,

d)  $>\text{NC}_{1-4}\text{alkyl}$ , where the alkyl is optionally substituted with a substituent selected from the group consisting of  $\text{NH}_2$ ,  $\text{NHC}_{1-4}\text{alkyl}$ ,  $\text{N}(\text{C}_{1-4}\text{alkyl})_2$ ,  $\text{CONH}_2$ ,  $\text{CONHC}_{1-4}\text{alkyl}$ ,  $\text{CON}(\text{C}_{1-4}\text{alkyl})_2$ ,  $\text{COOH}$ ,  $\text{COOC}_{1-4}\text{alkyl}$ ,  $\text{OH}$  and  $\text{OC}_{1-4}\text{alkyl}$ ;

$\text{R}_d$  is independently selected from the group consisting of  $\text{H}$  and  $\text{C}_{1-4}\text{alkyl}$ ;

$\text{R}_e$  is independently selected from the group consisting of  $\text{H}$  and optionally mono or di-substituted  $\text{C}_{1-4}\text{alkyl}$ , where the substituent is independently selected from the group consisting of  $\text{NH}_2$ ,  $\text{NHC}_{1-4}\text{alkyl}$ ,  $\text{N}(\text{C}_{1-4}\text{alkyl})_2$ ,  $\text{CONH}_2$ ,  $\text{CONHC}_{1-4}\text{alkyl}$ ,  $\text{CON}(\text{C}_{1-4}\text{alkyl})_2$ ,  $\text{COOH}$ ,  $\text{COOC}_{1-4}\text{alkyl}$ ,  $\text{CN}$ ,  $\text{OH}$  and  $\text{OC}_{1-4}\text{alkyl}$ ;

alternatively,  $\text{R}_d$  and  $\text{R}_e$  may be taken together with their atoms of attachment to form a 5 to 8 membered heterocyclic ring, with the heterocyclic ring having 0 or 1 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0 or 1 additional heteroatom members separated from an atom of attachment by at least one carbon member and selected from  $\text{O}$ ,  $\text{S}$ ,  $\text{N}=\text{}$ ,  $>\text{NH}$  or  $>\text{NC}_{1-4}\text{alkyl}$  and having a maximum of two heteroatom ring members;

$\text{R}_f$  is independently selected from the group consisting of  $\text{H}$ ,  $\text{CONH}_2$ ,  $\text{CONHC}_{1-4}\text{alkyl}$ ,  $\text{CON}(\text{C}_{1-4}\text{alkyl})_2$ ,  $\text{COOH}$ ,  $\text{COOC}_{1-4}\text{alkyl}$  and optionally mono or di-substituted  $\text{C}_{1-4}\text{alkyl}$ , where the substituent is independently selected from the group consisting of  $\text{NH}_2$ ,  $\text{NHC}_{1-4}\text{alkyl}$ ,  $\text{N}(\text{C}_{1-4}\text{alkyl})_2$ ,  $\text{CONH}_2$ ,  $\text{CONHC}_{1-4}\text{alkyl}$ ,  $\text{CON}(\text{C}_{1-4}\text{alkyl})_2$ ,  $\text{COOH}$ ,  $\text{COOC}_{1-4}\text{alkyl}$ ,  $\text{CN}$ ,  $\text{OH}$  and  $\text{OC}_{1-4}\text{alkyl}$ ;

$\text{R}_g$  is independently selected from the group consisting of  $\text{H}$  and optionally mono or di-substituted  $\text{C}_{1-4}\text{alkyl}$ , where the substituent is independently selected from the group consisting of  $\text{NH}_2$ ,  $\text{NHC}_{1-4}\text{alkyl}$ ,  $\text{N}(\text{C}_{1-4}\text{alkyl})_2$ ,  $\text{CONH}_2$ ,  $\text{CONHC}_{1-4}\text{alkyl}$ ,  $\text{CON}(\text{C}_{1-4}\text{alkyl})_2$ ,  $\text{COOH}$ ,  $\text{COOC}_{1-4}\text{alkyl}$ ,  $\text{CN}$ ,  $\text{OH}$  and  $\text{OC}_{1-4}\text{alkyl}$ ;

~~alternatively, R<sub>d</sub> and R<sub>g</sub> may be taken together with their nitrogen of common attachment to form a 5 to 8 membered heterocyclic ring, with the heterocyclic ring having 0 or 1 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0 or 1 additional heteroatom members separated from the atom of common attachment by at least one carbon member and selected from O, S, N=, >NH or >NC<sub>1-4</sub>alkyl;~~

~~R<sub>h</sub> is independently selected from the group consisting of H, and optionally mono or di-substituted C<sub>1-4</sub>alkyl, where the substituent is independently selected from the group consisting of NH<sub>2</sub>, NHC<sub>1-4</sub>alkyl, N(C<sub>1-4</sub>alkyl)<sub>2</sub>, CN, OH and OC<sub>1-4</sub>alkyl; or, alternatively, R<sub>h</sub> is CH<sub>2</sub>CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, optionally substituted with R<sub>i</sub>, which is bonded to a carbon of A adjacent to the carbon of Z attachment, forming a five or six membered carbocyclic ring;~~

~~R<sub>i</sub> is independently selected from the group consisting of H, OH, OC<sub>1-4</sub>alkyl and optionally mono or di-substituted C<sub>1-4</sub>alkyl, where the substituent is independently selected from the group consisting of NH<sub>2</sub>, NHC<sub>1-4</sub>alkyl, N(C<sub>1-4</sub>alkyl)<sub>2</sub>, CONH<sub>2</sub>, CONHC<sub>1-4</sub>alkyl, CON(C<sub>1-4</sub>alkyl)<sub>2</sub>, COOH, COOC<sub>1-4</sub>alkyl, CN, OH and OC<sub>1-4</sub>alkyl;~~

~~A is selected from the group consisting of:~~

~~a) phenyl, optionally mono-, di- or tri-substituted with R<sub>p</sub>;~~

~~R<sub>p</sub> is selected from the group consisting of -OH, -C<sub>1-6</sub>alkyl, -OC<sub>1-6</sub>alkyl, -C<sub>3-6</sub>cycloalkyl, -OC<sub>3-6</sub>cycloalkyl, -CN, -NO<sub>2</sub>, -N(R<sub>y</sub>)R<sub>z</sub> (wherein R<sub>y</sub> and R<sub>z</sub> are independently selected from -H or -C<sub>1-6</sub>alkyl, or may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >O, =N-, >NH or >N(C<sub>1-4</sub>alkyl) and optionally having one or two unsaturated bonds in the ring), -(C=O)N(R<sub>y</sub>)R<sub>z</sub>, -(N-R<sub>i</sub>)COR<sub>t</sub> (wherein R<sub>t</sub> is independently -H or -C<sub>1-6</sub>alkyl), -(N-R<sub>i</sub>)SO<sub>2</sub>C<sub>1-6</sub>alkyl, -(C=O)C<sub>1-6</sub>alkyl, -(S(=O)<sub>n</sub>)-C<sub>1-6</sub>alkyl (wherein n is selected from 0, 1 or 2), -SO<sub>2</sub>N(R<sub>y</sub>)R<sub>z</sub>, -SCF<sub>3</sub>, halo, -CF<sub>3</sub>, -OCF<sub>3</sub>, -COOH, -C<sub>1-6</sub>alkylCOOH, -COOC<sub>1-6</sub>alkyl and -C<sub>1-6</sub>alkylCOOC<sub>1-6</sub>alkyl;~~

- ~~b) phenyl, attached at two adjacent ring members to a C<sub>3-5</sub>alkyl moiety to form a fused 5 to 7 membered ring, said fused ring optionally having a second unsaturated bond, said fused ring optionally having one or two members replaced with =N-, >O-, >NH or >N(C<sub>1-4</sub>alkyl) except that no such replacement is permitted where the fused ring is 5 membered and has a second unsaturated bond, and said fused ring optionally having one carbon member replaced with >C=O, the fused rings optionally mono-, di- or tri-substituted with R<sub>p</sub>;~~
- ~~c) a monocyclic aromatic hydrocarbon group having six ring carbon atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by N, and optionally mono- or di-substituted with R<sub>p</sub>;~~
- ~~d) a monocyclic aromatic hydrocarbon group having six ring carbon atoms, having a carbon atom which is the point of attachment, having zero, one or two carbon atoms replaced by N, and having attachment at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by >O-, >S-, >NH or >N(C<sub>1-4</sub>alkyl) and which moiety has up to one additional carbon atom optionally replaced by N, the fused rings optionally mono-, di- or tri-substituted with R<sub>p</sub>;~~
- ~~e) a monocyclic aromatic hydrocarbon group having six ring carbon atoms, having a carbon atom which is the point of attachment, having zero, one or two carbon atoms replaced by N, and having attachment at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has zero, one or two carbon atoms replaced by N, the fused rings optionally mono-, di- or tri-substituted with R<sub>p</sub>;~~
- ~~f) a monocyclic aromatic hydrocarbon group having five ring carbon atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >O-, >S-, >NH or >N(C<sub>1-4</sub>alkyl), having up~~

~~to one additional carbon atom optionally replaced by N, and optionally mono- or di-substituted with R<sub>p</sub>;~~


- ~~g) a monocyclic aromatic hydrocarbon group having five ring carbon atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >O, >S, >NH or >N(C<sub>1-4</sub>alkyl), and having attachment at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has zero, one or two carbon atoms replaced by N, the fused rings optionally mono-, di- or tri-substituted with R<sub>p</sub>;~~
- ~~h) a 4-7 membered aliphatic or heterocyclic ring said heterocyclic ring having a carbon atom which is the point of attachment, having 0 or 1 heteroatom members selected from O, S, N=, >NH or >NR<sub>p</sub>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R<sub>p</sub>;~~
- ~~i) a benzo-fused 4-7 membered aliphatic or heterocyclic ring said heterocyclic ring having a carbon atom which is the point of attachment, having 0 or 1 additional heteroatom members selected from O, S, N=, >NH or >NR<sub>p</sub>, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents R<sub>p</sub>;~~

and enantiomers, diastereomers and pharmaceutically acceptable salts, esters or amides thereof.

2. (original) The compound of claim 1 wherein W is -(CO)NH<sub>2</sub>.
3. (original) The compound of claim 1 wherein Q is CH.
4. (original) The compound of claim 1 wherein R<sub>a</sub> and R<sub>b</sub> are -H, -Cl or -F.
5. (original) The compound of claim 1 wherein R<sub>a</sub> is -H and R<sub>b</sub> is -Cl or -F.


6. (original) The compound of claim 1 wherein  $R_a$  and  $R_b$  are -H.
7. (original) The compound of claim 1 wherein  $R_c$  is absent or is selected from the group consisting of -OH, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -F, -Cl, -Br, -I, -CF<sub>3</sub> and -OCH<sub>3</sub>.
8. (original) The compound of claim 1 wherein  $R_c$  is selected from the group consisting of -F, -Cl, -CH<sub>3</sub> and -OCH<sub>3</sub>.
9. (original) The compound of claim 1 wherein  $R_c$  is absent.
10. (canceled) The compound of claim 1 wherein  $R_d$  is selected from the group consisting of -H, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub> and -C(CH<sub>3</sub>)<sub>3</sub>.
11. (canceled) The compound of claim 1 wherein  $R_d$  is selected from the group consisting of -H, -CH<sub>3</sub> and -CH<sub>2</sub>CH<sub>3</sub>.
12. (canceled) The compound of claim 1 wherein  $R_e$  is selected from the group consisting of -H, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub> and -C(CH<sub>3</sub>)<sub>3</sub>, where the alkyl members are optionally mono- or di-substituted.
13. (canceled) The compound of claim 1 wherein  $R_e$  is selected from the group consisting of -H, -CH<sub>3</sub> and -CH<sub>2</sub>CH<sub>3</sub>, where the alkyl members are optionally mono- or di-substituted.
14. (canceled) The compound of claim 1 wherein  $R_e$  is -H or -CH<sub>3</sub>.

15. (canceled) The compound of claim 1 wherein  $R_d$  and  $R_e$  taken together with their atoms of attachment form a heterocyclic ring selected from the group consisting of




said heterocyclic ring having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl, where Y is selected from O, S, -N=, >NH or >NC<sub>1-4</sub>alkyl.

16. (canceled) The compound of claim 1 wherein  $R_d$  and  $R_e$  taken together with their atoms of attachment form a heterocyclic ring selected from the group consisting of




where Y is selected from O, >NH or >NC<sub>1-4</sub>alkyl.

17. (canceled) The compound of claim 1 wherein  $R_d$  and  $R_e$  taken together with their atoms of attachment form a heterocyclic ring selected from the group consisting of



18. (canceled) The compound of claim 1 wherein  $R_d$  and  $R_e$  taken together with their atoms of attachment form a heterocyclic ring selected from the group consisting of



19. (canceled) The compound of claim 1 wherein  $R_f$  is selected from the group consisting of -H, -CONH<sub>2</sub>, -CONHCH<sub>3</sub>, -CONHCH<sub>2</sub>CH<sub>3</sub>, -CON(CH<sub>3</sub>)<sub>2</sub>, -CON(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, -COOH, -COOCH<sub>3</sub>, -COOCH<sub>2</sub>CH<sub>3</sub>, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub> and -C(CH<sub>3</sub>)<sub>3</sub>, where the alkyl members are optionally mono- or di-substituted.

20. (canceled) The compound of claim 1 wherein  $R_f$  is selected from the group consisting of -H, -CONH<sub>2</sub>, -CONHCH<sub>3</sub>, -CON(CH<sub>3</sub>)<sub>2</sub>, -COOH, -COOCH<sub>3</sub>, -CH<sub>3</sub> and -CH<sub>2</sub>CH<sub>3</sub>, where the alkyl members are optionally mono- or di-substituted.


21. (canceled) The compound of claim 1 wherein  $R_f$  is selected from the group consisting of -H and -CH<sub>3</sub>.

22. (canceled) The compound of claim 1 wherein  $R_g$  is selected from the group consisting of -H, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub> and -C(CH<sub>3</sub>)<sub>3</sub>, where the alkyl moieties are optionally mono- or di-substituted.

23. (canceled) The compound of claim 1 wherein  $R_g$  is selected from the group consisting of -H, -CH<sub>3</sub> and -CH<sub>2</sub>CH<sub>3</sub> where the alkyl members are optionally mono- or di-substituted.




24. (canceled) The compound of claim 1 wherein  $R_d$  and  $R_g$  taken together with their nitrogen of attachment to form a heterocyclic ring are selected from the group consisting of




the heterocyclic ring having 0 or 1 unsaturated bonds and having 0, 1 or 2 carbon members which is a carbonyl, where Y is selected from O, S, -N=, >NH or >NC<sub>1-4</sub>alkyl.

25. (canceled) The compound of claim 1 wherein  $R_d$  and  $R_g$  taken together with their atoms of attachment to form a heterocyclic ring are selected from the group consisting of



Y is selected from O, S, >NH or >NC<sub>1-4</sub>alkyl.

26. (canceled) The compound of claim 1 wherein  $R_d$  and  $R_g$  taken together with their atoms of attachment to form a heterocyclic ring are selected from the group consisting of



where Y is selected from O, S, >NH or >NC<sub>1-4</sub>alkyl.

27. (canceled) The compound of claim 1 wherein  $R_h$  is selected from the group consisting of -H, -CONH<sub>2</sub>, -CONHCH<sub>3</sub>, -CONHCH<sub>2</sub>CH<sub>3</sub>, -CON(CH<sub>3</sub>)<sub>2</sub>, -CON(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, -COOH, -COOCH<sub>3</sub>, -COOCH<sub>2</sub>CH<sub>3</sub>, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>,

-CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub> and -C(CH<sub>3</sub>)<sub>3</sub>, where the alkyl members are optionally mono- or di-substituted.

28. (canceled) The compound of claim 1 wherein R<sub>h</sub> is selected from the group consisting of -H, -CONH<sub>2</sub>, -CONHCH<sub>3</sub>, -CON(CH<sub>3</sub>)<sub>2</sub>, -COOH, -COOCH<sub>3</sub>, -CH<sub>3</sub> and -CH<sub>2</sub>CH<sub>3</sub>, where the alkyl members are optionally mono- or di-substituted.

29. (canceled) The compound of claim 1 wherein R<sub>h</sub> is selected from the group consisting of -H, -CH<sub>3</sub> and -CH<sub>2</sub>CH<sub>3</sub>.

30. (canceled) The compound of claim 1 wherein R<sub>h</sub> is -CH<sub>2</sub>CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, which is bonded to a carbon of A adjacent to the carbon of Z attachment, forming a five- or six-membered carbocyclic ring.


31. (canceled) The compound of claim 1 wherein R<sub>h</sub> is -CH<sub>2</sub>CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, which taken together with A forms indanyl or 1,2,3,4-tetrahydronaphthalenyl.

32. (canceled) The compound of claim 1 wherein R<sub>i</sub> is selected from the group consisting of -H, -OH, -OCH<sub>3</sub>, -OCH<sub>2</sub>CH<sub>3</sub>, -OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>3</sub> and -C(CH<sub>3</sub>)<sub>3</sub>, where the directly attached alkyl members are optionally mono- or di-substituted.

33. (canceled) The compound of claim 1 wherein R<sub>i</sub> is selected from the group consisting of -H, -OH, -OCH<sub>3</sub>, -CH<sub>3</sub> and -CH<sub>2</sub>CH<sub>3</sub>, where the directly attached alkyl members are optionally mono- or di-substituted.


34. (canceled) The compound of claim 1 wherein Z is selected from the group consisting of

a) >C=O, >C=CH<sub>2</sub>, >CH<sub>2</sub>, >CHC<sub>1-4</sub>alkyl, >CF<sub>2</sub>, >CHOH, >CHOC<sub>1-4</sub>alkyl,




b)  $>\text{CHNR}_d\text{R}_g$ ,

c)  $-\text{SO}_2\text{NR}_d\text{CH}(\text{R}_h)-$ ,



where A is fused at the c face, at a face of A which contains two carbon atoms, which is saturated or unsaturated,




where A is fused at the c face, at a face of A which contains two carbon atoms, which is saturated or unsaturated,


d)  $>\text{NCH}_3$ ,  $>\text{NCH}_2\text{CH}_3$ ,  $>\text{NCH}_2\text{CH}_2\text{CH}_3$ ,  $>\text{NCH}(\text{CH}_3)_2$ ,  $>\text{NCH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  
and  $>\text{NCH}(\text{CH}_3)\text{CH}_2\text{CH}_3$ , where the alkyl attached to  $>\text{N}$  is optionally substituted.

35. (canceled) The compound of claim 1 wherein Z is selected from the group consisting of

a)  $>\text{C}=\text{O}$ ,  $>\text{C}=\text{CHR}_f$ ,  $>\text{CHR}_d$ ,  $>\text{CF}_2$ ,  $>\text{CHOR}_e$ ,




b)  $>\text{CHNHR}_g$ ,  $>\text{CHNCH}_3\text{R}_g$ ,




where Y is selected from O, S,  $-\text{N}=\text{}$ ,  $>\text{NH}$  or  $>\text{NC}_{1-4}\text{alkyl}$

c)  $-\text{SO}_2\text{NHCH}_2-$ ,  $-\text{SO}_2\text{NCH}_3\text{CH}_2-$ ,



where A is fused at the c face, at a face of A which contains two carbon atoms, which is saturated or unsaturated,



where A is fused at the c face, at a face of A which contains two carbon atoms, which is saturated or unsaturated,

d)  $>\text{NCH}_3$ ,  $>\text{NCH}_2\text{CH}_3$ ,  $>\text{NCH}_2\text{CH}_2\text{CH}_3$ ,  $>\text{NCH}(\text{CH}_3)_2$ , where the alkyl attached to  $>\text{N}$  is optionally substituted.

36. (canceled) The compound of claim 1 wherein A, optionally substituted with  $\text{R}_p$ , is selected from the group consisting of:

- a) phenyl,
- b) tetralin-5, 6, 7 or 8-yl, chroman-5, 6, 7 or 8-yl, benzo-1,2-pyran-5, 6, 7 or 8-yl, benzo-2,3-pyran-5, 6, 7 or 8-yl, coumarin-5, 6, 7 or 8-yl, isocoumarin-5, 6, 7 or 8-yl, benzo-1,3,2-benzoxazin-5, 6, 7 or 8-yl, benzo-1,4-dioxan-5, 6, 7 or 8-yl, 1,2,3,4-tetrahydroquinolin-5, 6, 7 or 8-yl, 1,2,3,4-tetrahydroquinoxalin-5, 6, 7 or 8-yl, thiochroman-5, 6, 7 or 8-yl, 2,3-dihydrobenzo[1,4]dithiin-5, 6, 7 or 8-yl, 1,2,3,4-tetrahydroisoquinolin-5, 6, 7 or 8-yl, indene-4, 5, 6, or 7-yl, 1, 2, 3, 4-tetrahydronaphth-5, 6, 7, or 8-yl, 1,2-dihydroisoindolo-4, 5, 6, or 7-yl, 2, 3-dihydroindene-4, 5, 6, or 7-yl, benzo-1,3-dioxol-4, 5, 6 or 7-yl, 2,3-dihydroindol-4, 5, 6 or 7-yl, 2,3-dihydrobenzofuran-4, 5, 6 or 7-yl, 2,3-dihydrobenzothiophen-4, 5, 6 or 7-yl, 2,3-dihydrobenzoimidazol-4, 5, 6 or 7-yl,
- c) pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl,
- d) benzoxazol-4, 5, 6 or 7-yl, benzothiophen-4, 5, 6 or 7-yl, benzofuran-4, 5, 6 or 7-yl, indol-4, 5, 6 or 7-yl, benzthiazol-4, 5, 6 or 7-yl, benzimidazo-4, 5, 6 or 7-yl, indazol-4, 5, 6 or 7-yl, 1H-pyrrolo[2,3-b]pyridin-4, 5 or 6-yl, 1H-pyrrolo[3,2-

- c)pyridin-4, 6 or 7-yl, 1H-pyrrolo[2,3-c]pyridin-4, 5 or 7-yl, 1H-pyrrolo[3,2-b]pyridin-5, 6 or 7-yl, purin-2-yl,
- e) isoquinolin-5, 6, 7 or 8-yl, quinolin-5, 6, 7 or 8-yl, quinoxalin-5, 6, 7 or 8-yl, quinazolin-5, 6, 7 or 8-yl, naphthyridinyl,
- f) furanyl, oxazolyl, isoxazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, and
- g) benzoxazol-2-yl, benzothiophen-2 or 3-yl, benzofuran-2 or 3-yl, indol-2 or 3yl, benzthiazol-2-yl, benzimidazo-2-yl, indazol-3-yl, 1H-pyrrolo[2,3-b]pyridin-2 or 3-yl, 1H-pyrrolo[3,2-c]pyridin-2 or 3-yl, 1H-pyrrolo[2,3-c]pyridin-2 or 3-yl, 1H-pyrrolo[3,2-b]pyridin-2 or 3-yl, purin-8-yl.

37. (canceled) The compound of claim 1 wherein A, optionally substituted with R<sub>p</sub>, is selected from the group consisting of:

- a) phenyl,
- b) coumarin-5, 6, 7 or 8-yl, benzo-1,4-dioxan-5, 6, 7 or 8-yl, 1,2,3,4-tetrahydroquinolin-5, 6, 7 or 8-yl, 1,2,3,4-tetrahydroisoquinolin-5, 6, 7 or 8-yl, indene-4, 5, 6, or 7-yl, 1,2,3,4-tetrahydronaph-5, 6, 7, or 8 yl, 1,2-dihydroisoindolo-4, 5, 6, or 7-yl, 2,3-dihydroindene-4, 5, 6, or 7-yl, benzo-1,3-dioxol-4, 5, 6 or 7-yl, 2,3-dihydroindol-4, 5, 6 or 7-yl, 2,3-dihydrobenzofuran-4, 5, 6 or 7-yl, 2,3-dihydrobenzothiophen-4, 5, 6 or 7-yl,
- c) pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl,
- d) benzothiophen-4, 5, 6 or 7-yl, benzofuran-4, 5, 6 or 7-yl, indol-4, 5, 6 or 7-yl,
- e) isoquinolin-5, 6, 7 or 8-yl, quinolin-5, 6, 7 or 8-yl,
- f) furanyl, oxazolyl, isoxazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrrolyl, imidazolyl, pyrazolyl, and
- g) benzoxazol-2-yl, benzothiophen-2 or 3-yl, benzofuran-2 or 3-yl, indol-2 or 3-yl.

38. (canceled) The compound of claim 1 wherein A, optionally substituted with R<sub>p</sub>, is selected from the group consisting of: phenyl, benzo-1,4-dioxan-5, 6, 7 or 8-yl, indene-4, 5, 6, or 7-yl, 1, 2, 3, 4-tetrahydronaph-5, 6, 7, or 8 yl, 2, 3-dihydroindene-4, 5, 6, or 7-yl, benzo-1,3-dioxol-4, 5, 6 or 7-yl, 2,3-dihydroindol-4,

5, 6 or 7-yl, 2,3-dihydrobenzofuran-4, 5, 6 or 7-yl, 2,3-dihydrobenzothiophen-4, 5, 6 or 7-yl, pyridinyl, benzothiophen-4, 5, 6 or 7-yl, benzofuran-4, 5, 6 or 7-yl, indol-4, 5, 6 or 7-yl, furanyl, thiophenyl, pyrrolyl, pyrazolyl, and benzothiophen-2 or 3-yl, benzofuran-2 or 3-yl and indol-2 or 3-yl.

39. (currently amended) The compound of claim 1 wherein A, including the R<sub>p</sub> substituent, is selected from the group consisting of ~~pyridyl~~, phenyl, ~~naphthyl~~, ~~quinolinyl~~, ~~cyclohexyl~~, 4-chloro phenyl, 4-methyl-3-chloro phenyl, 4-chloro-3-trifluoromethyl phenyl, 3,4-dichloro phenyl, 3-chloro-4-fluoro phenyl, 2-fluoro-5-trifluoromethyl phenyl, 4-chloro-3-fluoro phenyl, 3,4-dimethyl phenyl, ~~2-naphthyl~~, 4-trifluoromethyl phenyl, 4-bromo phenyl, 4-fluoro-3-methyl phenyl, 3-chloro phenyl, ~~tetrahydronaphthyl~~, 5-chloro-2-methyl phenyl, 3-trifluoromethyl phenyl, 4-methoxy phenyl, 4-methyl phenyl, 3,4-dimethyl phenyl, 2-fluoro-3-trifluoromethyl phenyl, 2-chloro-4-methyl phenyl, 4-ethyl phenyl, 4-fluoro phenyl, 3,4-dimethoxy phenyl, 3,4-dimethoxy-5-bromo phenyl, 3-(dimethylamino) phenyl, 4-nitro phenyl, 4-cyano phenyl, 2-methoxy-4-methyl phenyl, 4-trifluoromethoxy phenyl, 2-chloro phenyl, 4-morpholino phenyl, 3-chloro phenyl, 2,3-dichloro phenyl, benzo[1,3]dioxolyl, benzo[1,4]dioxinyl, 4-amino phenyl, 4-hydroxy phenyl, 4-bromo-3-hydroxy phenyl, 4-chloro-2-hydroxy phenyl, 4-chloro-3-hydroxy phenyl, 2,4-dichloro phenyl, 4-bromo-3-methoxy phenyl and 4-iodo phenyl.

40. (currently amended) The compound of claim 1 wherein A, including the R<sub>p</sub> substituent, is selected from the group consisting of phenyl, 4-chlorophenyl, 4-methylphenyl, 4-methoxyphenyl, ~~2-naphthalenyl~~, 4-chloro-3-trifluoromethylphenyl, 3-bromo-4,5-dimethoxyphenyl, 3,4-dichlorophenyl, 3,4-dimethylphenyl, 4-ethylphenyl, ~~benzo[1,3]dioxolyl~~, ~~2,3-dihydro-benzo[1,4]dioxinyl~~, ~~3-quinolinyl~~, ~~4-pyridyl~~, ~~cyclohexyl~~, ~~4-tetrahydropyranyl~~, ~~2-thiophenyl~~, ~~6-chloro-benzo[1,3]dioxolyl~~, 2-chlorophenyl, 2,4-dichlorophenyl, 2-methoxyphenyl, 2-methylphenyl, and 3-methylphenyl, and 2-furanyl.

41. (original) The compound of claim 1 wherein R<sub>p</sub> is selected from the group consisting of -OH, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -OCH<sub>3</sub>, -OCH<sub>2</sub>CH<sub>3</sub>, -OCH(CH<sub>3</sub>)<sub>2</sub>, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -Ocyclopentyl, -Ocyclohexyl, -CN, -NO<sub>2</sub>, -C(O)NH<sub>2</sub>, -C(O)N(CH<sub>3</sub>)<sub>2</sub>, -C(O)NH(CH<sub>3</sub>), -NHCOCH<sub>3</sub>, -NCH<sub>3</sub>COCH<sub>3</sub>, -NHSO<sub>2</sub>CH<sub>3</sub>, -NCH<sub>3</sub>SO<sub>2</sub>CH<sub>3</sub>, -C(O)CH<sub>3</sub>, -SOCH<sub>3</sub>, -SO<sub>2</sub>CH<sub>3</sub>, -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NHCH<sub>3</sub>, -SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, -SCF<sub>3</sub>, -F, -Cl, -Br, I, -CF<sub>3</sub>, -OCF<sub>3</sub>, -COOH, -COOCH<sub>3</sub>, -COOCH<sub>2</sub>CH<sub>3</sub>, -NH<sub>2</sub>, -NHCH<sub>3</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, -N(CH<sub>2</sub>CH<sub>3</sub>)<sub>2</sub>, -NCH<sub>3</sub>(CH(CH<sub>3</sub>)<sub>2</sub>), imidazolidin-1-yl, 2-imidazolin-1-yl, pyrazolidin-1-yl, piperidin-1-yl, 2- or 3-pyrrolin-1-yl, 2-pyrazolinyl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl, pyrrolidin-1-yl, homopiperidin-1-yl.

42. (original) The compound of claim 1 wherein R<sub>p</sub> is selected from the group consisting of -H, -OH, -OCH<sub>3</sub>, -OCF<sub>3</sub>, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CF<sub>3</sub>, -F, -Cl, -Br, -I, -NH<sub>2</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, morpholin-4-yl, -NO<sub>2</sub>, -CN, -C(O)NH<sub>2</sub>, -COOH, -NHSO<sub>2</sub>CH<sub>3</sub>, -SO<sub>2</sub>NH<sub>2</sub>.

43. (currently amended) The compound of claim 1 selected from the group consisting of:

~~2-[4-(2-Phenyl-[1,3]dioxolan-2-yl)-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-[2-(4-Chloro-phenyl)-[1,3]dioxolan-2-yl]-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

2-(4-Benzoyl-phenyl)-1H-benzoimidazole-5-carboxylic acid amide;

2-[4-(4-Chloro-benzoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide;

2-[4-(4-Methyl-benzoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide;

2-[4-(4-Methoxy-benzoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide;

~~2-[4-(Naphthalene-2-carbonyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

2-[4-(4-Chloro-3-trifluoromethyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide;

2-[4-(3-Bromo-4,5-dimethoxy-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide;

2-[4-(3,4-Dichloro-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide;

2-[4-(3,4-Dimethyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide;

2-[4-(4-Ethyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide;

~~2-[4-(Benzo[1,3]dioxole-5-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide;~~

~~2-[4-(2,3-Dihydro-benzo[1,4]dioxine-6-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide;~~

~~2-[4-(Quinoline-3-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide;~~

~~2-[4-(Pyridine-4-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide;~~

~~2-[4-(Cyclohexanecarbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide;~~

~~2-[4-(4-Chloro-benzoyl)-phenyl]-1*H*-benzoimidazole-5-sulfonic acid amide;~~

~~2-[4-(Hydroxy-phenyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide;~~

~~2-[4-[(4-Chloro-phenyl)-hydroxy-methyl]-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide;~~

~~2-[4-(Hydroxy-p-tolyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide;~~

~~2-[4-[Hydroxy-(4-methoxy-phenyl)-methyl]-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide;~~



~~2-[4-(Hydroxy-naphthalen-2-yl-methyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-[(4-Chloro-3-trifluoromethyl-phenyl)-hydroxy-methyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-[(3-Bromo-4,5-dimethoxy-phenyl)-hydroxy-methyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-[(3,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-[(3,4-Dimethyl-phenyl)-hydroxy-methyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-[(4-Ethyl-phenyl)-hydroxy-methyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-(Benzo[1,3]dioxol-5-yl-hydroxy-methyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-[(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-hydroxy-methyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-(Hydroxy-quinolin-3-yl-methyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-(Hydroxy-pyridin-4-yl-methyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-(Cyclohexyl-hydroxy-methyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-(Methoxy-phenyl-methyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-(4-Chloro-benzyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-(Naphthalen-2-ylmethyl-phenyl)-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-(3,4-Dimethyl-benzyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-(4-Ethyl-benzyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid  
amide;~~

~~2-[4-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-phenyl]-1H-  
benzoimidazole-5-carboxylic acid-amide;~~

~~2-(4-Cyclohexylmethyl-phenyl)-1H-benzoimidazole-5-carboxylic acid  
amide;~~

~~2-[4-[1-(4-Chloro-phenyl)-vinyl]-phenyl]-1H-benzoimidazole-5-  
carboxylic acid-amide;~~

~~2-[4-[1-(4-Chloro-phenyl)-ethyl]-phenyl]-1H-benzoimidazole-5-  
carboxylic acid-amide;~~

~~2-[4-[(4-Chloro-phenyl)-piperazin-1-yl-methyl]-phenyl]-1H-  
benzoimidazole-5-carboxylic acid-amide;~~

~~2-(4-[(4-Chloro-phenyl)-[methyl-(2-methylamino-ethyl)-amino]-methyl]-  
phenyl)-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-(Methyl-phenyl-amino)-phenyl]-1H-benzoimidazole-5-carboxylic  
acid-amide;~~

~~2-(4-Benzylsulfamoyl-phenyl)-1H-benzoimidazole-5-carboxylic acid  
amide;~~

~~2-[4-(4-Methyl-benzylsulfamoyl)-phenyl]-1H-benzoimidazole-5-  
carboxylic acid-amide;~~

~~2-[4-(4-Methoxy-benzylsulfamoyl)-phenyl]-1H-benzoimidazole-5-  
carboxylic acid-amide;~~

~~2-[4-(4-Chloro-benzylsulfamoyl)-phenyl]-1H-benzoimidazole-5-  
carboxylic acid-amide;~~

~~2-[4-(3,4-Dichloro-benzylsulfamoyl)-phenyl]-1H-benzoimidazole-5-  
carboxylic acid-amide;~~

~~2-[4-(Benzyl-methyl-sulfamoyl)-phenyl]-1H-benzoimidazole-5-carboxylic  
acid-amide;~~

~~2-[4-(Tetrahydro-pyran-4-carbonyl)-phenyl]-1H-benzoimidazole-5-  
carboxylic acid-amide;~~

~~2-[4-(Thiophene-2-carbonyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-(6-Chloro-benzo[1,3]dioxole-5-carbonyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-(2-Chloro-benzoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide;~~

~~2-[4-(2,4-Dichloro-benzoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide;~~

~~2-[4-(2-Methoxy-benzoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide;~~

~~2-[4-(2-Methyl-benzoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide;~~

~~2-[4-[Hydroxy-(tetrahydro-pyran-4-yl)-methyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-(Hydroxy-thiophen-2-yl-methyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-[(6-Chloro-benzo[1,3]dioxol-5-yl)-hydroxy-methyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-[(2-Chloro-phenyl)-hydroxy-methyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-[(2,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-[Hydroxy-(2-methoxy-phenyl)-methyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-(Hydroxy-o-tolyl-methyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-(6-Chloro-benzo[1,3]dioxol-5-ylmethyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid-amide;~~

~~2-[4-(2-Methoxy-benzyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide;~~

~~2-[4-(2-Methyl-benzyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid  
amide;  
2-[4-(2-Methyl-benzylsulfamoyl)-phenyl]-1H-benzoimidazole-5-  
carboxylic acid amide;  
2-[4-(3-Methyl-benzylsulfamoyl)-phenyl]-1H-benzoimidazole-5-  
carboxylic acid amide;  
2-[4-(1,3-Dihydro-isoindole-2-sulfonyl)-phenyl]-1H-benzoimidazole-5-  
carboxylic acid amide;  
2-[4-(2,3-Dihydro-indole-1-sulfonyl)-phenyl]-1H-benzoimidazole-5-  
carboxylic acid amide;  
(±)-2-[4-(1-Phenyl-ethylsulfamoyl)-phenyl]-1H-benzoimidazole-5-  
carboxylic acid amide;  
(±)-2-[4-(1,2,3,4-Tetrahydro-naphthalen-1-ylsulfamoyl)-phenyl]-1H-  
benzoimidazole-5-carboxylic acid amide;  
2-[4-[(Thiophen-2-ylmethyl)-sulfamoyl]-phenyl]-1H-benzoimidazole-5-  
carboxylic acid amide;  
2-[4-[(Furan-2-ylmethyl)-sulfamoyl]-phenyl]-1H-benzoimidazole-5-  
carboxylic acid amide;  
2-[4-[(Pyridin-4-ylmethyl)-sulfamoyl]-phenyl]-1H-benzoimidazole-5-  
carboxylic acid amide; and  
2-[4-(S)-Indan-1-ylsulfamoyl]-phenyl]-1H-benzoimidazole-5-carboxylic  
acid amide.~~

44. (canceled) The compound of claim 1 selected from the group consisting of: 2-[4-[1-(4-Chloro-phenyl)-vinyl]-phenyl]-1H-imidazo[4,5-b]pyridine-5-carboxylic acid amide; 2-[4-[(2,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-(3,4-Dihydro-1H-isoquinoline-2-sulfonyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-(4-Thiophen-2-ylmethyl-phenyl)-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-(Furan-3-carbonyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-(Furan-3-yl-hydroxy-methyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-(4-Furan-

3-ylmethyl-phenyl)-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(1-Methyl-1*H*-imidazole-2-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[Hydroxy-(1-methyl-1*H*-imidazol-2-yl)-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(1-Methyl-1*H*-imidazol-2-ylmethyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(5-Chloro-thiophene-2-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(5-Chloro-thiophen-2-yl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(5-Chloro-thiophen-2-ylmethyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Piperidine-4-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-piperidin-4-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-(4-Piperidin-4-ylmethyl-phenyl)-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Tetrahydro-thiopyran-4-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[Hydroxy-(tetrahydro-thiopyran-4-yl)-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Tetrahydro-thiopyran-4-ylmethyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Tetrahydro-pyran-4-ylmethyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; [[4-(5-Carbamoyl-1*H*-benzoimidazol-2-yl)-phenyl]-(4-chloro-phenyl)-methoxy]-acetic acid; 2-{4-[(2-Amino-ethoxy)-(4-chloro-phenyl)-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(4-Chloro-phenyl)-difluoro-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Benzo[1,3]dioxol-5-yl-difluoro-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[1-(4-Chloro-phenyl)-1-methyl-ethyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(4-Chloro-phenyl)-cyano-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-((*S*)-1-Hydroxymethyl-1,3-dihydro-isoindole-2-sulfonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-((*R*)-1-Hydroxymethyl-1,3-dihydro-isoindole-2-sulfonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-((1*R*,2*S*)-2-Hydroxy-indan-1-ylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-((*S*)-2-Hydroxy-1-phenyl-ethylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-((*R*)-2-Hydroxy-1-phenyl-ethylsulfamoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid

amide; and 2-[4-[(Pyridin-2-ylmethyl)-sulfamoyl]-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide.

45. (currently amended) The compound of claim 1 selected from the group consisting of: 2-[4-(4-Methyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Naphthalene-2-carbonyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(4-Chloro-3-trifluoromethyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(3-Bromo-4,5-dimethoxy-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(3,4-Dichloro-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(3,4-Dimethyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(4-Ethyl-benzoyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-Cyclohexanecarbonyl-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-phenyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-[(4-Chloro-phenyl)-hydroxy-methyl]-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-[(Hydroxy-*p*-tolyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-[(Hydroxy-(4-methoxy-phenyl)-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-naphthalen-2-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-[(4-Chloro-3-trifluoromethyl-phenyl)-hydroxy-methyl]-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-[(3,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-[(3,4-Dimethyl-phenyl)-hydroxy-methyl]-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-[(4-Ethyl-phenyl)-hydroxy-methyl]-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Benzo[1,3]dioxol-5-yl-hydroxy-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-quinolin-3-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(4-Chloro-benzyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-(4-Naphthalen-2-ylmethyl-phenyl)-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(3,4-Dimethyl-benzyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(4-Ethyl-benzyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-phenyl]-1*H*-benzoimidazole-5-


~~carboxylic acid amide; 2-[4-[1-(4-Chloro-phenyl)-vinyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-[1-(4-Chloro-phenyl)-ethyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-(1,3-Dihydro-isoindole-2-sulfonyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-(2,3-Dihydro-indole-1-sulfonyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; (±)-2-[4-(1,2,3,4-Tetrahydro-naphthalen-1-ylsulfamoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-[(Thiophen-2-ylmethyl)-sulfamoyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; and 2-[4-(Indan(S)-1-ylsulfamoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide.~~

46. (currently amended) The compound of claim 1 selected from the group consisting of: ~~2-[4-(Naphthalene-2-carbonyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-(3,4-Dichloro-benzoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-[(4-Chloro-phenyl)-hydroxy-methyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-naphthalen-2-yl-methyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-[(4-Chloro-3-trifluoromethyl-phenyl)-hydroxy-methyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-[(3,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-[(3,4-Dimethyl-phenyl)-hydroxy-methyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-quinolin-3-yl-methyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-(4-Chloro-benzyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-(Naphthalen-2-ylmethyl-phenyl)-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-(3,4-Dimethyl-benzyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-[1-(4-Chloro-phenyl)-vinyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-[1-(4-Chloro-phenyl)-ethyl]-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; 2-[4-(1,3-Dihydro-isoindole-2-sulfonyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide; and 2-[4-(S)-Indan-1-ylsulfamoyl)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide.~~

47. (canceled) The compound of claim 1 selected from the group consisting of: 2-[4-(Hydroxy-phenyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(4-Chloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-*p*-tolyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[Hydroxy-(4-methoxy-phenyl)-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-naphthalen-2-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(4-Chloro-3-trifluoromethyl-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(3-Bromo-4,5-dimethoxy-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(3,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(3,4-Dimethyl-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(4-Ethyl-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Benzo[1,3]dioxol-5-yl-hydroxy-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-quinolin-3-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-pyridin-4-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Cyclohexyl-hydroxy-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[Hydroxy-(tetrahydro-pyran-4-yl)-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-thiophen-2-yl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(6-Chloro-benzo[1,3]dioxol-5-yl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(2-Chloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[(2,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-{4-[Hydroxy-(2-methoxy-phenyl)-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide; 2-[4-(Hydroxy-*o*-tolyl-methyl)-phenyl]-1*H*-benzoimidazole-5-carboxylic acid amide; and 2-{4-[(2,4-Dichloro-phenyl)-hydroxy-methyl]-phenyl}-1*H*-benzoimidazole-5-carboxylic acid amide.



48. (currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a Cds-1 inhibiting amount of a compound of the formula:



wherein

W is  $-\text{COOH}$ ,  $-(\text{CO})\text{NH}_2$ , or  $-(\text{SO}_2)\text{NH}_2$ ;

Q is N or CH;

$R_a$  and  $R_b$  are independently selected from -H and halogen;


$R_c$  is absent or is independently selected from the group consisting of  $-\text{OH}$ ,  $-\text{CF}_3$ ,  $-\text{C}_{1-4}\text{alkyl}$ ,  $-\text{OC}_{1-4}\text{alkyl}$ ,  $-\text{NO}_2$  and halo;

Z is selected from the group consisting of


a)  $>\text{C}=\text{O}$ ,  $>\text{C}=\text{CHR}_f$ ,  $>\text{CR}_d\text{R}_g$ ,  $>\text{CF}_2$ ,  $>\text{CR}_d\text{OR}_e$ ,  $>\text{C}(\text{OR}_d)\text{OR}_e$ ,

b)  $>\text{C}(\text{R}_d)\text{NR}_d\text{R}_g$ ,

c)  $-\text{SO}_2\text{NR}_d\text{C}(\text{R}_h)_2$ ,



where A is fused at the b or c faces, at a face of A which contains two carbon atoms, which is saturated or unsaturated,



where A is fused at the b or c faces, at a face of A which contains two carbon atoms, which is saturated or unsaturated,

d)  $>\text{NC}_{1-4}\text{alkyl}$ , where the alkyl is optionally substituted with a substituent selected from the group consisting of  $-\text{NH}_2$ ,  $-\text{NHC}_{1-4}\text{alkyl}$ ,  $-\text{N}(\text{C}_{1-4}\text{alkyl})_2$ ,  $-\text{CONH}_2$ ,  $-\text{CONHC}_{1-4}\text{alkyl}$ ,  $-\text{CON}(\text{C}_{1-4}\text{alkyl})_2$ ,  $-\text{COOH}$ ,  $-\text{COOC}_{1-4}\text{alkyl}$ ,  $-\text{OH}$  and  $-\text{OC}_{1-4}\text{alkyl}$ ;

~~R<sub>d</sub> is independently selected from the group consisting of H and C<sub>1-4</sub>alkyl;~~  
~~R<sub>e</sub> is independently selected from the group consisting of H and optionally~~  
~~mono or di-substituted C<sub>1-4</sub>alkyl, where the substituent is independently~~  
~~selected from the group consisting of NH<sub>2</sub>, NHC<sub>1-4</sub>alkyl, N(C<sub>1-4</sub>alkyl)<sub>2</sub>,~~  
~~-CONH<sub>2</sub>, -CONHC<sub>1-4</sub>alkyl, -CON(C<sub>1-4</sub>alkyl)<sub>2</sub>, -COOH, -COOC<sub>1-4</sub>alkyl, -CN, -OH~~  
~~and -OC<sub>1-4</sub>alkyl;~~

~~alternatively, R<sub>d</sub> and R<sub>e</sub> may be taken together with their atoms of attachment to~~  
~~form a 5 to 8 membered heterocyclic ring, with the heterocyclic ring having 0~~  
~~or 1 unsaturated bonds, having 0, 1 or 2 carbon members which is a~~  
~~carbonyl, having 0 or 1 additional heteroatom members separated from an~~  
~~atom of attachment by at least one carbon member and selected from O, S,~~  
~~-N=, >NH or >NC<sub>1-4</sub>alkyl and having a maximum of two heteroatom ring~~  
~~members;~~

~~R<sub>f</sub> is independently selected from the group consisting of H, -CONH<sub>2</sub>,~~  
~~-CONHC<sub>1-4</sub>alkyl, -CON(C<sub>1-4</sub>alkyl)<sub>2</sub>, -COOH, -COOC<sub>1-4</sub>alkyl and optionally~~  
~~mono or di-substituted C<sub>1-4</sub>alkyl, where the substituent is independently~~  
~~selected from the group consisting of NH<sub>2</sub>, NHC<sub>1-4</sub>alkyl, N(C<sub>1-4</sub>alkyl)<sub>2</sub>,~~  
~~-CONH<sub>2</sub>, -CONHC<sub>1-4</sub>alkyl, -CON(C<sub>1-4</sub>alkyl)<sub>2</sub>, -COOH, -COOC<sub>1-4</sub>alkyl, -CN, -OH~~  
~~and -OC<sub>1-4</sub>alkyl;~~

~~R<sub>g</sub> is independently selected from the group consisting of H and optionally~~  
~~mono or di-substituted C<sub>1-4</sub>alkyl, where the substituent is independently~~  
~~selected from the group consisting of NH<sub>2</sub>, NHC<sub>1-4</sub>alkyl, N(C<sub>1-4</sub>alkyl)<sub>2</sub>,~~  
~~-CONH<sub>2</sub>, -CONHC<sub>1-4</sub>alkyl, -CON(C<sub>1-4</sub>alkyl)<sub>2</sub>, -COOH, -COOC<sub>1-4</sub>alkyl, -CN, -OH~~  
~~and -OC<sub>1-4</sub>alkyl;~~

~~alternatively, R<sub>d</sub> and R<sub>g</sub> may be taken together with their nitrogen of common~~  
~~attachment to form a 5 to 8 membered heterocyclic ring, with the heterocyclic~~  
~~ring having 0 or 1 unsaturated bonds, having 0, 1 or 2 carbon members which~~  
~~is a carbonyl and having 0 or 1 additional heteroatom members separated~~  
~~from the atom of common attachment by at least one carbon member and~~  
~~selected from O, S, -N=, >NH or >NC<sub>1-4</sub>alkyl;~~

~~R<sub>h</sub> is independently selected from the group consisting of H, and optionally mono- or di-substituted C<sub>1-4</sub>alkyl, where the substituent is independently selected from the group consisting of NH<sub>2</sub>, NHG<sub>1-4</sub>alkyl, N(C<sub>1-4</sub>alkyl)<sub>2</sub>, CN, -OH and -OC<sub>1-4</sub>alkyl; or, alternatively, R<sub>h</sub> is -CH<sub>2</sub>CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, optionally substituted with R<sub>i</sub>, which is bonded to a carbon of A adjacent to the carbon of Z attachment, forming a five- or six-membered carbocyclic ring;~~

~~R<sub>i</sub> is independently selected from the group consisting of H, OH, -OC<sub>1-4</sub>alkyl and optionally mono- or di-substituted C<sub>1-4</sub>alkyl, where the substituent is independently selected from the group consisting of NH<sub>2</sub>, NHG<sub>1-4</sub>alkyl, -N(C<sub>1-4</sub>alkyl)<sub>2</sub>, -CONH<sub>2</sub>, -CONHG<sub>1-4</sub>alkyl, -CON(C<sub>1-4</sub>alkyl)<sub>2</sub>, -COOH, -COOC<sub>1-4</sub>alkyl, -CN, -OH and -OC<sub>1-4</sub>alkyl;~~

~~A is selected from the group consisting of:~~

~~a) phenyl, optionally mono-, di- or tri-substituted with R<sub>p</sub>;~~

~~R<sub>p</sub> is selected from the group consisting of -OH, -C<sub>1-6</sub>alkyl, -OC<sub>1-6</sub>alkyl, -C<sub>3-6</sub>cycloalkyl, -OC<sub>3-6</sub>cycloalkyl, -CN, -NO<sub>2</sub>, -N(R<sub>y</sub>)R<sub>z</sub> (wherein R<sub>y</sub> and R<sub>z</sub> are independently selected from -H or -C<sub>1-6</sub>alkyl, or may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with >O, =N-, >NH or >N(C<sub>1-4</sub>alkyl) and optionally having one or two unsaturated bonds in the ring), -(C=O)N(R<sub>y</sub>)R<sub>z</sub>, -(N-R<sub>i</sub>)COR<sub>i</sub> (wherein R<sub>i</sub> is independently -H or -C<sub>1-6</sub>alkyl), -(N-R<sub>i</sub>)SO<sub>2</sub>C<sub>1-6</sub>alkyl, -(C=O)C<sub>1-6</sub>alkyl, -(S(O)<sub>n</sub>)-C<sub>1-6</sub>alkyl (wherein n is selected from 0, 1 or 2), -SO<sub>2</sub>N(R<sub>y</sub>)R<sub>z</sub>, -SCF<sub>3</sub>, halo, -CF<sub>3</sub>, -OCF<sub>3</sub>, -COOH, -C<sub>1-6</sub>alkylCOOH, -COOC<sub>1-6</sub>alkyl and -C<sub>1-6</sub>alkylCOOC<sub>1-6</sub>alkyl;~~

~~b) phenyl, attached at two adjacent ring members to a C<sub>3-5</sub>alkyl moiety to form a fused 5 to 7 membered ring, said fused ring optionally having a second unsaturated bond, said fused ring optionally having one or two members replaced with =N-, >O, >NH or >N(C<sub>1-4</sub>alkyl) except that no such replacement is permitted where the fused ring is 5 membered and has a second unsaturated bond, and said fused ring optionally~~

- ~~having one carbon member replaced with  $>C=O$ , the fused rings optionally mono-, di- or tri-substituted with  $R_p$ ;~~
- ~~e) a monocyclic aromatic hydrocarbon group having six ring carbon atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by N, and optionally mono- or di-substituted with  $R_p$ ;~~
- ~~d) a monocyclic aromatic hydrocarbon group having six ring carbon atoms, having a carbon atom which is the point of attachment, having zero, one or two carbon atoms replaced by N, and having attachment at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring, which moiety has one carbon atom replaced by  $>O$ ,  $>S$ ,  $>NH$  or  $>N(C_{1-4}alkyl)$  and which moiety has up to one additional carbon atom optionally replaced by N, the fused rings optionally mono-, di- or tri-substituted with  $R_p$ ;~~
- ~~e) a monocyclic aromatic hydrocarbon group having six ring carbon atoms, having a carbon atom which is the point of attachment, having zero, one or two carbon atoms replaced by N, and having attachment at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has zero, one or two carbon atoms replaced by N, the fused rings optionally mono-, di- or tri-substituted with  $R_p$ ;~~
- ~~f) a monocyclic aromatic hydrocarbon group having five ring carbon atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by  $>O$ ,  $>S$ ,  $>NH$  or  $>N(C_{1-4}alkyl)$ , having up to one additional carbon atom optionally replaced by N, and optionally mono- or di-substituted with  $R_p$ ;~~
- ~~g) a monocyclic aromatic hydrocarbon group having five ring carbon atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by  $>O$ ,  $>S$ ,  $>NH$  or  $>N(C_{1-4}alkyl)$ , and having attachment at two adjacent carbon ring members to a four~~


~~membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has zero, one or two carbon atoms replaced by N, the fused rings optionally mono-, di- or tri-substituted with  $R_p$ ;~~

~~h) a 4-7 membered aliphatic or heterocyclic ring said heterocyclic ring having a carbon atom which is the point of attachment, having 0 or 1 heteroatom members selected from O, S, N=, >NH or >NR<sub>p</sub>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents  $R_p$ ;~~

~~i) a benzo fused 4-7 membered aliphatic or heterocyclic ring said heterocyclic ring having a carbon atom which is the point of attachment, having 0 or 1 additional heteroatom members selected from O, S, N=, >NH or >NR<sub>p</sub>, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents  $R_p$ ;~~

and enantiomers, diastereomers and pharmaceutically acceptable salts, esters or amides thereof.

49. (withdrawn) A method for treating a subject suffering from cancer, said method comprising (a) administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of the formula given below, and (b) damaging the DNA of said subject by administering a DNA damaging treatment or agent:



wherein

W is -COOH, -(CO)NH<sub>2</sub>, or -(SO<sub>2</sub>)NH<sub>2</sub>;

Q is N or CH;

R<sub>a</sub> and R<sub>b</sub> are independently selected from -H and halogen;


$R_c$  is absent or is independently selected from the group consisting of  $-\text{OH}$ ,  $-\text{CF}_3$ ,  $-\text{C}_{1-4}\text{alkyl}$ ,  $-\text{OC}_{1-4}\text{alkyl}$ ,  $-\text{NO}_2$  and halo;

Z is selected from the group consisting of


a)  $>\text{C}=\text{O}$ ,  $>\text{C}=\text{CHR}_f$ ,  $>\text{CR}_d\text{R}_d$ ,  $>\text{CF}_2$ ,  $>\text{CR}_d\text{OR}_e$ ,  $>\text{C}(\text{OR}_d)\text{OR}_e$ ,

b)  $>\text{C}(\text{R}_d)\text{NR}_d\text{R}_g$ ,

c)  $-\text{SO}_2\text{NR}_d\text{C}(\text{R}_h)_2-$ ,



where A is fused at the b or c faces, at a face of A which contains two carbon atoms, which is saturated or unsaturated,



where A is fused at the b or c faces, at a face of A which contains two carbon atoms, which is saturated or unsaturated,

d)  $>\text{NC}_{1-4}\text{alkyl}$ , where the alkyl is optionally substituted with a substituent selected from the group consisting of  $-\text{NH}_2$ ,  $-\text{NHC}_{1-4}\text{alkyl}$ ,  $-\text{N}(\text{C}_{1-4}\text{alkyl})_2$ ,  $-\text{CONH}_2$ ,  $-\text{CONHC}_{1-4}\text{alkyl}$ ,  $-\text{CON}(\text{C}_{1-4}\text{alkyl})_2$ ,  $-\text{COOH}$ ,  $-\text{COOC}_{1-4}\text{alkyl}$ ,  $-\text{OH}$  and  $-\text{OC}_{1-4}\text{alkyl}$ ;

$R_d$  is independently selected from the group consisting of  $-\text{H}$  and  $-\text{C}_{1-4}\text{alkyl}$ ;

$R_e$  is independently selected from the group consisting of  $-\text{H}$  and optionally mono- or di-substituted  $-\text{C}_{1-4}\text{alkyl}$ , where the substituent is independently selected from the group consisting of  $-\text{NH}_2$ ,  $-\text{NHC}_{1-4}\text{alkyl}$ ,  $-\text{N}(\text{C}_{1-4}\text{alkyl})_2$ ,  $-\text{CONH}_2$ ,  $-\text{CONHC}_{1-4}\text{alkyl}$ ,  $-\text{CON}(\text{C}_{1-4}\text{alkyl})_2$ ,  $-\text{COOH}$ ,  $-\text{COOC}_{1-4}\text{alkyl}$ ,  $-\text{CN}$ ,  $-\text{OH}$  and  $-\text{OC}_{1-4}\text{alkyl}$ ;

alternatively,  $R_d$  and  $R_e$  may be taken together with their atoms of attachment to form a 5 to 8 membered heterocyclic ring, with the heterocyclic ring having 0 or 1 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0 or 1 additional heteroatom members separated from an

atom of attachment by at least one carbon member and selected from O, S, -N=, >NH or >NC<sub>1-4</sub>alkyl and having a maximum of two heteroatom ring members;

R<sub>f</sub> is independently selected from the group consisting of -H, -CONH<sub>2</sub>, -CONHC<sub>1-4</sub>alkyl, -CON(C<sub>1-4</sub>alkyl)<sub>2</sub>, -COOH, -COOC<sub>1-4</sub>alkyl and optionally mono- or di-substituted C<sub>1-4</sub>alkyl, where the substituent is independently selected from the group consisting of -NH<sub>2</sub>, -NHC<sub>1-4</sub>alkyl, -N(C<sub>1-4</sub>alkyl)<sub>2</sub>, -CONH<sub>2</sub>, -CONHC<sub>1-4</sub>alkyl, -CON(C<sub>1-4</sub>alkyl)<sub>2</sub>, -COOH, -COOC<sub>1-4</sub>alkyl, -CN, -OH and -OC<sub>1-4</sub>alkyl;

R<sub>g</sub> is independently selected from the group consisting of -H and optionally mono- or di-substituted -C<sub>1-4</sub>alkyl, where the substituent is independently selected from the group consisting of -NH<sub>2</sub>, -NHC<sub>1-4</sub>alkyl, -N(C<sub>1-4</sub>alkyl)<sub>2</sub>, -CONH<sub>2</sub>, -CONHC<sub>1-4</sub>alkyl, -CON(C<sub>1-4</sub>alkyl)<sub>2</sub>, -COOH, -COOC<sub>1-4</sub>alkyl, -CN, -OH and -OC<sub>1-4</sub>alkyl;

alternatively, R<sub>d</sub> and R<sub>g</sub> may be taken together with their nitrogen of common attachment to form a 5 to 8 membered heterocyclic ring, with the heterocyclic ring having 0 or 1 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0 or 1 additional heteroatom members separated from the atom of common attachment by at least one carbon member and selected from O, S, -N=, >NH or >NC<sub>1-4</sub>alkyl;

R<sub>h</sub> is independently selected from the group consisting of -H, and optionally mono- or di-substituted C<sub>1-4</sub>alkyl, where the substituent is independently selected from the group consisting of -NH<sub>2</sub>, -NHC<sub>1-4</sub>alkyl, -N(C<sub>1-4</sub>alkyl)<sub>2</sub>, -CN, -OH and -OC<sub>1-4</sub>alkyl; or, alternatively, R<sub>h</sub> is -CH<sub>2</sub>CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, optionally substituted with R<sub>i</sub>, which is bonded to a carbon of A adjacent to the carbon of Z attachment, forming a five- or six-membered carbocyclic ring;

R<sub>i</sub> is independently selected from the group consisting of -H, -OH, -OC<sub>1-4</sub>alkyl and optionally mono- or di-substituted C<sub>1-4</sub>alkyl, where the substituent is independently selected from the group consisting of -NH<sub>2</sub>, -NHC<sub>1-4</sub>alkyl, -N(C<sub>1-4</sub>alkyl)<sub>2</sub>, -CONH<sub>2</sub>, -CONHC<sub>1-4</sub>alkyl, -CON(C<sub>1-4</sub>alkyl)<sub>2</sub>, -COOH, -COOC<sub>1-4</sub>alkyl, -CN, -OH and -OC<sub>1-4</sub>alkyl;

A is selected from the group consisting of:

- a) phenyl, optionally mono-, di- or tri-substituted with  $R_p$ ;  
 $R_p$  is selected from the group consisting of  $-OH$ ,  $-C_{1-6}alkyl$ ,  $-OC_{1-6}alkyl$ ,  $-C_{3-6}cycloalkyl$ ,  $-OC_{3-6}cycloalkyl$ ,  $-CN$ ,  $-NO_2$ ,  $-N(R_y)R_z$  (wherein  $R_y$  and  $R_z$  are independently selected from  $-H$  or  $-C_{1-6}alkyl$ , or may be taken together with the nitrogen of attachment to form an otherwise aliphatic hydrocarbon ring, said ring having 5 to 7 members, optionally having one carbon replaced with  $>O$ ,  $=N-$ ,  $>NH$  or  $>N(C_{1-4}alkyl)$  and optionally having one or two unsaturated bonds in the ring),  $-(C=O)N(R_y)R_z$ ,  $-(N-R_t)COR_t$  (wherein  $R_t$  is independently  $-H$  or  $-C_{1-6}alkyl$ ),  $-(N-R_t)SO_2C_{1-6}alkyl$ ,  $-(C=O)C_{1-6}alkyl$ ,  $-(S=(O)_n)-C_{1-6}alkyl$  (wherein  $n$  is selected from 0, 1 or 2),  $-SO_2N(R_y)R_z$ ,  $-SCF_3$ , halo,  $-CF_3$ ,  $-OCF_3$ ,  $-COOH$ ,  $-C_{1-6}alkylCOOH$ ,  $-COOC_{1-6}alkyl$  and  $-C_{1-6}alkylCOOC_{1-6}alkyl$ ;
- b) phenyl, attached at two adjacent ring members to a  $C_{3-5}alkyl$  moiety to form a fused 5 to 7 membered ring, said fused ring optionally having a second unsaturated bond, said fused ring optionally having one or two members replaced with  $=N-$ ,  $>O$ ,  $>NH$  or  $>N(C_{1-4}alkyl)$  except that no such replacement is permitted where the fused ring is 5 membered and has a second unsaturated bond, and said fused ring optionally having one carbon member replaced with  $>C=O$ , the fused rings optionally mono-, di- or tri-substituted with  $R_p$ ;
- c) a monocyclic aromatic hydrocarbon group having six ring carbon atoms, having a carbon atom which is the point of attachment, having one or two carbon atoms replaced by N, and optionally mono- or di-substituted with  $R_p$ ;
- d) a monocyclic aromatic hydrocarbon group having six ring carbon atoms, having a carbon atom which is the point of attachment, having zero, one or two carbon atoms replaced by N, and having attachment at two adjacent carbon ring members to a three membered hydrocarbon moiety to form a fused five membered aromatic ring,



which moiety has one carbon atom replaced by >O, >S, >NH or >N(C<sub>1-4</sub>alkyl) and which moiety has up to one additional carbon atom optionally replaced by N, the fused rings optionally mono-, di- or tri-substituted with R<sub>p</sub>;

- e) a monocyclic aromatic hydrocarbon group having six ring carbon atoms, having a carbon atom which is the point of attachment, having zero, one or two carbon atoms replaced by N, and having attachment at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has zero, one or two carbon atoms replaced by N, the fused rings optionally mono-, di- or tri-substituted with R<sub>p</sub>;
- f) a monocyclic aromatic hydrocarbon group having five ring carbon atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >O, >S, >NH or >N(C<sub>1-4</sub>alkyl), having up to one additional carbon atom optionally replaced by N, and optionally mono- or di-substituted with R<sub>p</sub>;
- g) a monocyclic aromatic hydrocarbon group having five ring carbon atoms, having a carbon atom which is the point of attachment, having one carbon atom replaced by >O, >S, >NH or >N(C<sub>1-4</sub>alkyl), and having attachment at two adjacent carbon ring members to a four membered hydrocarbon moiety to form a fused six membered aromatic ring, which moiety has zero, one or two carbon atoms replaced by N, the fused rings optionally mono-, di- or tri-substituted with R<sub>p</sub>;
- h) a 4-7 membered aliphatic or heterocyclic ring said heterocyclic ring having a carbon atom which is the point of attachment, having 0 or 1 heteroatom members selected from O, S, -N=, >NH or >NR<sub>p</sub>, having 0, 1 or 2 unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl and having 0, 1 or 2 substituents R<sub>p</sub>,
- i) a benzo fused 4-7 membered aliphatic or heterocyclic ring said heterocyclic ring having a carbon atom which is the point of attachment, having 0 or 1 additional heteroatom members selected

from O, S, -N=, >NH or >NR<sub>p</sub>, having 0 or 1 additional unsaturated bonds, having 0, 1 or 2 carbon members which is a carbonyl, having 0, 1, 2, or 3 halo substituents on the benzene ring only and having 0, 1 or 2 substituents R<sub>p</sub>,

and enantiomers, diastereomers and pharmaceutically acceptable salts, esters or amides thereof.

50. (withdrawn) A compound of claim 1 isotopically-labelled to be detectable by PET or SPECT.

51. (withdrawn) A method for studying cancer comprising the step of using an <sup>18</sup>F-labeled or <sup>11</sup>C-labelled compound of claim 1 as a positron emission tomography (PET) molecular probe.